×
About 37,428 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  17,441 results

Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with ac...
https://doi.org/10.1002/pbc.29051
Pediatric Blood & Cancer; McCormick M, Lapinski J et. al.

Apr 16th, 2021 - PEG-asparaginase is critical in pediatric acute lymphoblastic leukemia (ALL) therapy but is highly immunogenic. Severe allergic reactions lead to substitution of further PEG-asparaginase with Erwinia. Erwinia is associated with more frequent dosin...

Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell...
https://doi.org/10.1111/petr.14024
Pediatric Transplantation; Bayram N, Yaman Y et. al.

Apr 16th, 2021 - (Ph-like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR-ABL1 translocation. We reported an exceptional case of a child with relapsed Ph-like ALL with IKZF1 gene deletion trea...

Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leuke...
https://doi.org/10.1016/j.it.2021.03.005
Trends in Immunology; Belver L, Albero R et. al.

Apr 16th, 2021 - Enhancers control dynamic changes in gene expression and orchestrate the tightly controlled transcriptional circuitries that direct and coordinate cell growth, proliferation, survival, lineage commitment, and differentiation during lymphoid develo...

In utero and early-life exposure to thirdhand smoke causes profound changes to the immu...
https://doi.org/10.1042/CS20201498
Clinical Science (London, England : 1979); Snijders AM, Zhou M et. al.

Apr 14th, 2021 - Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Thirdhand smoke (THS) is the residual tobacco contamination that remains after the smoke clears. We investigated the effects of THS exposure in utero and during early life i...

Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric...
https://doi.org/10.1182/blood.2020009515
Blood Wudhikarn K, Flynn JR et. al.

Apr 14th, 2021 - CD19-targeted chimeric antigen receptor (CAR) T cell therapy has become a breakthrough treatment for patients with relapsed/refractory B acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult p...

see more →

Guidelines  45 results

Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 13th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

Children with Down syndrome, ALL at higher risk for poor outcomes
https://www.healio.com/hematology-oncology/leukemia/news/online/{4b3c1cc4-4e4a-462e-b738-7ee6b1d20fd3}/children-with-down-syndrome-all-at-higher-risk-for-poor-outcomes

May 30th, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.

Strict Cytogenetics, MRD Criteria Identifies Pediatric B-ALL Subgroup With Favorable Prognosis
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200195/full/

May 28th, 2020 - Application of a set of stringent clinical and cytogenetic features as well as minimal residual disease (MRD) criteria can identify a subset of low-risk (LR) pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who can...

Tisagenlecleucel Outcomes in Trial of Pediatric, Young Adult R/R ALL Are Consistent With Those Previously Reported
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200130/full/

May 12th, 2020 - In pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) who received prior blinatumomab exposure or inotuzumab ozogamicin as bridging therapy, treatment with tisagenlecleucel is associated with consistent ...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 7th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

see more →

Drugs  203 results see all →

Clinicaltrials.gov  18,547 results

Premedication prior to PEG-asparaginase is cost-effective in pediatric patients with ac...
https://doi.org/10.1002/pbc.29051
Pediatric Blood & Cancer; McCormick M, Lapinski J et. al.

Apr 16th, 2021 - PEG-asparaginase is critical in pediatric acute lymphoblastic leukemia (ALL) therapy but is highly immunogenic. Severe allergic reactions lead to substitution of further PEG-asparaginase with Erwinia. Erwinia is associated with more frequent dosin...

Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell...
https://doi.org/10.1111/petr.14024
Pediatric Transplantation; Bayram N, Yaman Y et. al.

Apr 16th, 2021 - (Ph-like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR-ABL1 translocation. We reported an exceptional case of a child with relapsed Ph-like ALL with IKZF1 gene deletion trea...

Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leuke...
https://doi.org/10.1016/j.it.2021.03.005
Trends in Immunology; Belver L, Albero R et. al.

Apr 16th, 2021 - Enhancers control dynamic changes in gene expression and orchestrate the tightly controlled transcriptional circuitries that direct and coordinate cell growth, proliferation, survival, lineage commitment, and differentiation during lymphoid develo...

In utero and early-life exposure to thirdhand smoke causes profound changes to the immu...
https://doi.org/10.1042/CS20201498
Clinical Science (London, England : 1979); Snijders AM, Zhou M et. al.

Apr 14th, 2021 - Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Thirdhand smoke (THS) is the residual tobacco contamination that remains after the smoke clears. We investigated the effects of THS exposure in utero and during early life i...

Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric...
https://doi.org/10.1182/blood.2020009515
Blood Wudhikarn K, Flynn JR et. al.

Apr 14th, 2021 - CD19-targeted chimeric antigen receptor (CAR) T cell therapy has become a breakthrough treatment for patients with relapsed/refractory B acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult p...

see more →

News  1,189 results

Allo-HSCT Plus MAb Can Boost Survival in Patients With r/r B-ALL
https://www.medscape.com/viewarticle/948153

Mar 24th, 2021 - The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in minimal residual disease (MRD)-negative remission patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) after the start...

Clear Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma
https://www.medscape.com/viewarticle/946711

Mar 2nd, 2021 - NEW YORK (Reuters Health) - Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favo...

TBI Beats Chemoconditioning for ALL Transplants in Children
https://www.medscape.com/viewarticle/945225

Feb 2nd, 2021 - For now at least, total body irradiation (TBI) plus etoposide remains the conditioning regimen of choice for children undergoing allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia (ALL), according to an open-label phase...

Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 13th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

'Impressive' Outcomes Sans Chemo in Poor-Prognosis ALL
https://www.staging.medscape.com/viewarticle/939520

Oct 20th, 2020 - The days of using chemotherapy to treat Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) may be numbered. In a phase 2 trial, up-front chemo-free induction/consolidation with the tyrosine kinase inhibitor dasatinib (Sprycel)...

see more →

Patient Education  3 results see all →